Ruiyi Medical is Drug Discovery in China that focus on new drug business. Founded in 2006. They cover business area such as operator, high-tech company, production, new-type medical organosilicon product, a number, domestically pioneer general-purpose reagent, new drug molecular building block, pharmaceutical company, medical organosilicon intermediate, pharmaceutical raw material intermediate, various phase, clinical trial.
2006
( 18 years old in 2024 )
New Drug
-
Room 601, North of Building 1, Neobay
No.951 Jianchuan Road, Minhang District
Shanghai
China
Private
operatorhigh-tech companyproductionnew-type medical organosilicon producta numberdomestically pioneer general-purpose reagentnew drug molecular building blockpharmaceutical companymedical organosilicon intermediatepharmaceutical raw material intermediatevarious phaseclinical trial
* We use standard office opening hours in near Ruiyi Medical's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ruiyi Medical is Drug Discovery business from China that founded in 2006 (18 years old in 2024), Ruiyi Medical business is focusing on New Drug.
Ruiyi Medical headquarter office and corporate office address is located in Room 601, North of Building 1, Neobay No.951 Jianchuan Road, Minhang District Shanghai China.
Ruiyi Medical was founded in China.
In 2024, Ruiyi Medical is currently focus on new drug sector.
Above is snippet of Google Trends for "new drug" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ruiyi Medical, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
